Switch to:
Also traded in: Germany, Mexico

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 0.05
ACT's Cash to Debt is ranked lower than
96% of the 768 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.45 vs. ACT: 0.05 )
Ranked among companies with meaningful Cash to Debt only.
ACT' s Cash to Debt Range Over the Past 10 Years
Min: 0.02  Med: 0.47 Max: 43.62
Current: 0.05
0.02
43.62
Equity to Asset 0.57
ACT's Equity to Asset is ranked lower than
60% of the 707 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.64 vs. ACT: 0.57 )
Ranked among companies with meaningful Equity to Asset only.
ACT' s Equity to Asset Range Over the Past 10 Years
Min: 0.25  Med: 0.61 Max: 0.93
Current: 0.57
0.25
0.93
F-Score: 6
Z-Score: 1.04
M-Score: -2.47
WACC vs ROIC
10.09%
-1.08%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) -12.34
ACT's Operating margin (%) is ranked lower than
81% of the 714 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.72 vs. ACT: -12.34 )
Ranked among companies with meaningful Operating margin (%) only.
ACT' s Operating margin (%) Range Over the Past 10 Years
Min: -21.33  Med: 6.99 Max: 14.12
Current: -12.34
-21.33
14.12
Net-margin (%) 26.25
ACT's Net-margin (%) is ranked higher than
92% of the 716 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.15 vs. ACT: 26.25 )
Ranked among companies with meaningful Net-margin (%) only.
ACT' s Net-margin (%) Range Over the Past 10 Years
Min: -22.48  Med: 5.41 Max: 25.98
Current: 26.25
-22.48
25.98
ROE (%) 5.87
ACT's ROE (%) is ranked lower than
55% of the 744 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.16 vs. ACT: 5.87 )
Ranked among companies with meaningful ROE (%) only.
ACT' s ROE (%) Range Over the Past 10 Years
Min: -23.54  Med: 6.44 Max: 12.05
Current: 5.87
-23.54
12.05
ROA (%) 3.38
ACT's ROA (%) is ranked lower than
52% of the 769 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.76 vs. ACT: 3.38 )
Ranked among companies with meaningful ROA (%) only.
ACT' s ROA (%) Range Over the Past 10 Years
Min: -13.02  Med: 3.54 Max: 6.67
Current: 3.38
-13.02
6.67
ROC (Joel Greenblatt) (%) -40.04
ACT's ROC (Joel Greenblatt) (%) is ranked lower than
79% of the 762 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 14.16 vs. ACT: -40.04 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
ACT' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -112.05  Med: 20.55 Max: 39.38
Current: -40.04
-112.05
39.38
Revenue Growth (3Y)(%) -3.80
ACT's Revenue Growth (3Y)(%) is ranked lower than
75% of the 602 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.40 vs. ACT: -3.80 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
ACT' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -3.8  Med: 17.50 Max: 39.8
Current: -3.8
-3.8
39.8
EBITDA Growth (3Y)(%) 0.80
ACT's EBITDA Growth (3Y)(%) is ranked lower than
64% of the 549 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.00 vs. ACT: 0.80 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
ACT' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -3.7  Med: 3.60 Max: 41.1
Current: 0.8
-3.7
41.1
» ACT's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-08-06)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Insider Trades

Latest Guru Trades with ACT

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Preferred stocks of Allergan PLC

SymbolPriceYieldDescription
AGNPRA845.696.585 1/2 % Cum.Conv.Pref.Shs 2015-1.3.18 Series -A-

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:NYSE:TEVA, TSE:4502, BOM:524715, NYSE:ZTS, NAS:MYL » details
Traded in other countries:A60.Germany, AGN N.Mexico,
Allergan PLC is a specialty pharmaceutical company. The Company is engaged in developing, manufacturing and distributing generic, brand and biosimilar products.

Allergan PLC, formerly known as Actavis PLC was incorporated in Ireland on May 16, 2013. It is an integrated specialty pharmaceutical company. The Company is engaged in development, manufacturing, marketing, sale and distribution of generic, branded generic, brand name, biosimilar and over-the-counter pharmaceutical products. It also develops and out-license generic pharmaceutical products in Europe through its Medis third-party business. It operates in three segments, Pharma, Specialty Brands and Anda Distribution. The Pharma segment includes off-patent pharmaceutical products that are therapeutically equivalent to proprietary products. The Specialty Brands segment includes patent-protected products and certain trademarked off-patent products that the Company sells and markets as brand pharmaceutical products. The Anda Distribution segment distributes generic and brand pharmaceutical products manufactured by third parties, as well as by the Company to independent pharmacies, pharmacy chains, pharmacy buying groups and physicians' offices. It competes with generic manufacturers of pharmaceutical products. It is subject to extensive, complex and evolving regulation by the federal government, the FDA, and to a lesser extent, by the U.S. Drug Enforcement Administration Occupational Safety and Health Administration and state government agencies, as well as by various regulatory agencies in foreign countries where its products or product candidates are being manufactured and/or marketed. The Federal Food, Drug and Cosmetic Act, the Controlled Substances Act and other federal statutes and regulations govern or influence the testing, manufacturing, packing, labeling, storing, record keeping, safety, approval, advertising, promotion, sale and distribution of its products.

Guru Investment Theses on Allergan PLC

Vanguard Health Care Fund Comments on Actavis PLC - Mar 27, 2015

Actavis (ACT) is a specialty pharmaceutical company that develops generic and branded products. We owned Actavis prior to its Forest Labs acquisition but increased our position. We are attracted to the uniqueness of the combined company’s business model, which provides exposure to both generic and branded pharmaceuticals globally. The company’s Irish tax rate could also be strategically important in future mergers and acquisitions. Actavis was the fund’s second-largest holding as of the end of the period.



From Vanguard Health Care Fund (Trades, Portfolio) 2014 Annual Report.



Check out Vanguard Health Care Fund latest stock trades

Bernard Horn Comments on Actavis PLC - Oct 30, 2014

On July 1, Actavis (ACT) announced the completion of its acquisition of Forest Laboratories Inc. (a Fund holding), in a cash and equity transaction valued at approximately $28 billion. We maintained a position in Actavis, as its pro-forma financial statements fit the Polaris valuation profile. As one of the largest generic pharmaceutical companies, Actavis is expected to broaden its product platform with the Forest acquisition, increase operating cash flow and realize $1 billion in cost synergies.

From Bernard Horn (Trades, Portfolio)’s Polaris Global Value Fund Q3 2014 Shareholder Letter.

Check out Bernard Horn latest stock trades

Diamond Hill Capital Comments on Actavis PLC - Jul 25, 2014

We eliminated our position in specialty pharmaceutical company Actavis PLC (ACT) as the price to intrinsic value relationship narrowed. We originally received shares when Actavis bought portfolio holding Warner Chilcott.

From Diamond Hill Capital (Trades, Portfolio)'s Small Cap Fund Second Quarter 2014 Commentary.

Check out Diamond Hill Capital latest stock trades

Diamond Hill Capital Comments on Actavis Inc - Jun 26, 2014

Pharmaceutical company Actavis, Inc. PLC (ACT) announced the acquisition of drug manufacturer Forest Laboratories, Inc. during the quarter for a combination of cash and stock. Investors viewed this as a positive for Actavis due to expected synergies and an increase in the branded drug business as a percent of revenues.



From Diamond Hill Capital's Small Cap Fund Commentary – First Quarter 2014.



Check out Diamond Hill Capital latest stock trades

Top Ranked Articles about Allergan PLC

John Paulson's First-Quarter Moves Alter Largest And Most Valuable Stakes
Hedge fund manager John Paulson (Trades, Portfolio), founder and president of Paulson & Co. Inc., the third-largest hedge fund in the world, has been called “one of the most prominent names in high finance” by The New York Times. He rocketed to prominence by making $3.7 billion in 2007 using credit default swaps in a gamble against the U.S. subprime mortgage lending market. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 20.53
ACT's P/E(ttm) is ranked higher than
64% of the 558 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 27.44 vs. ACT: 20.53 )
Ranked among companies with meaningful P/E(ttm) only.
ACT' s P/E(ttm) Range Over the Past 10 Years
Min: 11.01  Med: 26.86 Max: 485.71
Current: 20.53
11.01
485.71
Forward P/E 12.82
ACT's Forward P/E is ranked higher than
56% of the 90 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 13.95 vs. ACT: 12.82 )
Ranked among companies with meaningful Forward P/E only.
N/A
Price/Owner Earnings (ttm) 32.37
ACT's Price/Owner Earnings (ttm) is ranked higher than
53% of the 265 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 33.19 vs. ACT: 32.37 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
ACT' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 8.13  Med: 18.41 Max: 675.82
Current: 32.37
8.13
675.82
P/B 1.25
ACT's P/B is ranked higher than
80% of the 762 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.80 vs. ACT: 1.25 )
Ranked among companies with meaningful P/B only.
ACT' s P/B Range Over the Past 10 Years
Min: 1.03  Med: 1.75 Max: 5.9
Current: 1.25
1.03
5.9
P/S 4.98
ACT's P/S is ranked lower than
68% of the 714 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.76 vs. ACT: 4.98 )
Ranked among companies with meaningful P/S only.
ACT' s P/S Range Over the Past 10 Years
Min: 0.99  Med: 1.84 Max: 17.57
Current: 4.98
0.99
17.57
PFCF 18.93
ACT's PFCF is ranked higher than
61% of the 199 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 26.71 vs. ACT: 18.93 )
Ranked among companies with meaningful PFCF only.
ACT' s PFCF Range Over the Past 10 Years
Min: 6.62  Med: 14.67 Max: 36.71
Current: 18.93
6.62
36.71
POCF 16.94
ACT's POCF is ranked higher than
54% of the 265 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 17.71 vs. ACT: 16.94 )
Ranked among companies with meaningful POCF only.
ACT' s POCF Range Over the Past 10 Years
Min: 5.97  Med: 12.09 Max: 31.19
Current: 16.94
5.97
31.19
EV-to-EBITDA 29.89
ACT's EV-to-EBITDA is ranked lower than
73% of the 569 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 16.81 vs. ACT: 29.89 )
Ranked among companies with meaningful EV-to-EBITDA only.
ACT' s EV-to-EBITDA Range Over the Past 10 Years
Min: -224.1  Med: 9.90 Max: 381.6
Current: 29.89
-224.1
381.6
Shiller P/E 799.24
ACT's Shiller P/E is ranked lower than
100% of the 146 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 46.77 vs. ACT: 799.24 )
Ranked among companies with meaningful Shiller P/E only.
ACT' s Shiller P/E Range Over the Past 10 Years
Min: 14.67  Med: 50.11 Max: 1172.22
Current: 799.24
14.67
1172.22
Current Ratio 0.99
ACT's Current Ratio is ranked lower than
88% of the 662 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.40 vs. ACT: 0.99 )
Ranked among companies with meaningful Current Ratio only.
ACT' s Current Ratio Range Over the Past 10 Years
Min: 0.99  Med: 2.89 Max: 9.8
Current: 0.99
0.99
9.8
Quick Ratio 0.89
ACT's Quick Ratio is ranked lower than
81% of the 662 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.87 vs. ACT: 0.89 )
Ranked among companies with meaningful Quick Ratio only.
ACT' s Quick Ratio Range Over the Past 10 Years
Min: 0.78  Med: 1.98 Max: 8.82
Current: 0.89
0.78
8.82
Days Inventory 127.22
ACT's Days Inventory is ranked lower than
57% of the 668 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 114.30 vs. ACT: 127.22 )
Ranked among companies with meaningful Days Inventory only.
ACT' s Days Inventory Range Over the Past 10 Years
Min: 75.66  Med: 119.26 Max: 133.19
Current: 127.22
75.66
133.19
Days Sales Outstanding 54.28
ACT's Days Sales Outstanding is ranked higher than
68% of the 620 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 74.15 vs. ACT: 54.28 )
Ranked among companies with meaningful Days Sales Outstanding only.
ACT' s Days Sales Outstanding Range Over the Past 10 Years
Min: 31.08  Med: 58.63 Max: 92.81
Current: 54.28
31.08
92.81
Days Payable 31.02
ACT's Days Payable is ranked lower than
85% of the 589 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 71.47 vs. ACT: 31.02 )
Ranked among companies with meaningful Days Payable only.
ACT' s Days Payable Range Over the Past 10 Years
Min: 18.72  Med: 59.11 Max: 107.57
Current: 31.02
18.72
107.57

Valuation & Return

vs
industry
vs
history
Price/Projected FCF 1.18
ACT's Price/Projected FCF is ranked higher than
81% of the 311 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.53 vs. ACT: 1.18 )
Ranked among companies with meaningful Price/Projected FCF only.
ACT' s Price/Projected FCF Range Over the Past 10 Years
Min: 0.61  Med: 1.17 Max: 3.29
Current: 1.18
0.61
3.29
Price/Median PS Value 2.71
ACT's Price/Median PS Value is ranked lower than
88% of the 680 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.09 vs. ACT: 2.71 )
Ranked among companies with meaningful Price/Median PS Value only.
ACT' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.67  Med: 1.36 Max: 8.52
Current: 2.71
0.67
8.52
Earnings Yield (Greenblatt) (%) -1.70
ACT's Earnings Yield (Greenblatt) (%) is ranked lower than
71% of the 782 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.00 vs. ACT: -1.70 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
ACT' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 1  Med: 6.20 Max: 12.3
Current: -1.7
1
12.3
Forward Rate of Return (Yacktman) (%) 2.16
ACT's Forward Rate of Return (Yacktman) (%) is ranked lower than
61% of the 323 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.36 vs. ACT: 2.16 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
ACT' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: -2.4  Med: 7.50 Max: 16.1
Current: 2.16
-2.4
16.1

More Statistics

Short Percentage of Float1.14%
52-Week Range $201.91 - 317.72
Shares Outstanding (Mil)392.44
» More Articles for ACT

Headlines

Articles On GuruFocus.com
'Party Drug' Could Be Johnson & Johnson's Entry Into Antidepressant Market May 22 2016 
John Paulson Trims Time Warner Cable, Starwood Hotels May 18 2016 
Seth Klarman's 5 New Buys May 13 2016 
The PBM Empire Strikes Back May 10 2016 
Baron Funds Comments on Allergan plc May 06 2016 
Jerome Dodson Sells Stake in Citrix Systems in 1st Quarter Apr 28 2016 
Weitz Funds Comments on Allergan Apr 25 2016 
Pfizer-Allergen Merger Deal End Hurts Some Funds But Helps Many Apr 08 2016 
Wilbur Ross Denounces Anti-Business 'Terrible Populist Sentiment' on CNBC Apr 07 2016 
2 Major Mergers Come to End After Tough Stance From Regulators Apr 07 2016 

More From Other Websites
10 Stocks George Soros Is Buying in 2016 May 27 2016
This Company Benefits From U.S. Treasury Rules May 16 2016
Allergan's Q1 revenue rises, income beats estimates after acquisition May 10 2016
Supernus Enters Into Partial Settlement Agreement with Actavis on Oxtellar XR® May 10 2016
Teva's (TEVA) Stock Gains on Q1 Earnings & Revenue Beat May 10 2016
Teva Pharm Q1 profit falls less than expected May 09 2016
VGHCX: Vanguard Health Care Fund Performance Case Study May 06 2016
Activist Investors Now Have Influence Without Spending A Dime May 04 2016
The Treasury is not killing inversions, but it wants to eventually Apr 05 2016
How Will Teva Benefit from Its Multiple Acquisitions? Mar 30 2016
Is Allergan on the Way to Becoming a New Leader? Mar 09 2016
Analyzing Actavis' Price & Profitability Ratios in 2016 (AGN) Mar 05 2016
Top 5 Positions in Daniel Loeb's Portfolio Feb 26 2016
10 Stocks George Soros Is Buying for 2016 Feb 18 2016
Teva's Q4 Earnings In-Line with Estimates, Gives Q1 Outlook Feb 12 2016
Teva says Actavis deal to close by April as profit falls Feb 11 2016
How Will Teva Finance the Actavis Acquisition? Jan 21 2016
How the Teva-Actavis Deal Benefits Teva Dec 07 2015
Allergan drops appeal of order blocking Alzheimer's drug switch Nov 25 2015
ALLERGAN PLC Files SEC form 8-K, Entry into a Material Definitive Agreement, Change in Directors or... Nov 24 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)